Compare Manhattan Associates Inc (MANH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs BIO-TECHNE Corp — how do they compare? Manhattan Associates Inc trades at $206.18 (market cap $11.79B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Manhattan Associates Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and BIO-TECHNE Corp for 63 Days on average.
| MANH | TECH | |
|---|---|---|
Market Cap | $11.79B | $11.37B |
Volume | 393,599 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $223.76 | $72.61 |
52-Week Low | $120.88 | $43.31 |
Typical Hold Time | 12 Days | 63 Days |
Enterprise Value | $11.66B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $202.11, down 0.36% on the day, with a bearish technical signal and key support at $201. The company shows strong profitability with a net income margin of 18.67% and has beaten earnings estimates for the last three quarters. Recent news includes a law firm investigation into fiduciary duties and a product launch of Editions for its supply chain solutions.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside to the $210.50 consensus target, but technical weakness and the ongoing legal investigation pose near-term risks. Earnings growth remains the key catalyst for further price appreciation.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
